Why sponsors need a global view of clinical trial compliance

17 May 2018

Francine Lane, vice president of global transparency at TrialScope, writes an Expert View on the challenges of meeting and exceeding differing disclosure expectations in different markets.

You are almost certainly conducting a clinical trial in a country that has some requirements around disclosing clinical trial data yet, like many trial sponsors, you may have only limited control and visibility into your global disclosure compliance. Clinical trials are conducted in almost every country in the world, and more than 90 of them have some requirements around disclosing clinical trial information.

Evolution of disclosure

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical